nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Irinotecan—colon cancer	0.275	0.454	CbGbCtD
Dabigatran etexilate—ABCB1—colon cancer	0.241	1	CbGaD
Dabigatran etexilate—CES1—Capecitabine—colon cancer	0.154	0.255	CbGbCtD
Dabigatran etexilate—CES1—Irinotecan—colon cancer	0.0954	0.158	CbGbCtD
Dabigatran etexilate—UGT1A9—Irinotecan—colon cancer	0.0579	0.0957	CbGbCtD
Dabigatran etexilate—F2—hepatic artery—colon cancer	0.0149	0.19	CbGeAlD
Dabigatran etexilate—F2—portal vein—colon cancer	0.0129	0.165	CbGeAlD
Dabigatran etexilate—ABCB1—Irinotecan—colon cancer	0.00939	0.0155	CbGbCtD
Dabigatran etexilate—ABCB1—Vincristine—colon cancer	0.00821	0.0136	CbGbCtD
Dabigatran etexilate—F2—vein—colon cancer	0.00744	0.095	CbGeAlD
Dabigatran etexilate—ABCB1—Methotrexate—colon cancer	0.00497	0.00822	CbGbCtD
Dabigatran etexilate—UGT2B15—gall bladder—colon cancer	0.00406	0.0518	CbGeAlD
Dabigatran etexilate—F2—endothelium—colon cancer	0.00256	0.0327	CbGeAlD
Dabigatran etexilate—F2—blood vessel—colon cancer	0.00236	0.0301	CbGeAlD
Dabigatran etexilate—F2—gall bladder—colon cancer	0.00222	0.0284	CbGeAlD
Dabigatran etexilate—CES1—gall bladder—colon cancer	0.00204	0.026	CbGeAlD
Dabigatran etexilate—UGT2B15—digestive system—colon cancer	0.0016	0.0204	CbGeAlD
Dabigatran etexilate—UGT1A9—renal system—colon cancer	0.00148	0.0188	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—colon cancer	0.00124	0.0158	CbGeAlD
Dabigatran etexilate—UGT1A9—digestive system—colon cancer	0.00121	0.0154	CbGeAlD
Dabigatran etexilate—UGT2B15—liver—colon cancer	0.00119	0.0152	CbGeAlD
Dabigatran etexilate—CES2—renal system—colon cancer	0.00119	0.0152	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—colon cancer	0.00119	0.0152	CbGeAlD
Dabigatran etexilate—F2—epithelium—colon cancer	0.00115	0.0147	CbGeAlD
Dabigatran etexilate—CES2—Irinotecan Pathway—APC—colon cancer	0.00111	0.0839	CbGpPWpGaD
Dabigatran etexilate—F2—renal system—colon cancer	0.00107	0.0136	CbGeAlD
Dabigatran etexilate—NQO2—renal system—colon cancer	0.00106	0.0136	CbGeAlD
Dabigatran etexilate—UGT2B7—digestive system—colon cancer	0.000975	0.0124	CbGeAlD
Dabigatran etexilate—CES2—digestive system—colon cancer	0.000975	0.0124	CbGeAlD
Dabigatran etexilate—UGT1A9—liver—colon cancer	0.000901	0.0115	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—colon cancer	0.000899	0.0115	CbGeAlD
Dabigatran etexilate—F2—lymphoid tissue—colon cancer	0.000886	0.0113	CbGeAlD
Dabigatran etexilate—F2—digestive system—colon cancer	0.000875	0.0112	CbGeAlD
Dabigatran etexilate—CES2—vagina—colon cancer	0.000861	0.011	CbGeAlD
Dabigatran etexilate—UGT2B7—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000813	0.0617	CbGpPWpGaD
Dabigatran etexilate—CES1—lymphoid tissue—colon cancer	0.000813	0.0104	CbGeAlD
Dabigatran etexilate—F2—bone marrow—colon cancer	0.000806	0.0103	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—colon cancer	0.000803	0.0102	CbGeAlD
Dabigatran etexilate—CES1—digestive system—colon cancer	0.000803	0.0102	CbGeAlD
Dabigatran etexilate—NQO2—vagina—colon cancer	0.00077	0.00982	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TYMS—colon cancer	0.000759	0.0576	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—liver—colon cancer	0.000727	0.00927	CbGeAlD
Dabigatran etexilate—CES2—liver—colon cancer	0.000727	0.00927	CbGeAlD
Dabigatran etexilate—CES1—Irinotecan Pathway—APC—colon cancer	0.000652	0.0495	CbGpPWpGaD
Dabigatran etexilate—F2—liver—colon cancer	0.000652	0.00831	CbGeAlD
Dabigatran etexilate—NQO2—liver—colon cancer	0.000649	0.00828	CbGeAlD
Dabigatran etexilate—CES1—liver—colon cancer	0.000598	0.00763	CbGeAlD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CHST4—colon cancer	0.000568	0.0431	CbGpPWpGaD
Dabigatran etexilate—CES2—lymph node—colon cancer	0.000557	0.00711	CbGeAlD
Dabigatran etexilate—ABCB1—blood vessel—colon cancer	0.000508	0.00648	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—colon cancer	0.000498	0.00635	CbGeAlD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CHST4—colon cancer	0.000461	0.035	CbGpPWpGaD
Dabigatran etexilate—CES1—lymph node—colon cancer	0.000459	0.00585	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TYMS—colon cancer	0.000448	0.0339	CbGpPWpGaD
Dabigatran etexilate—Chest discomfort—Capecitabine—colon cancer	0.000424	0.00675	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Vincristine—colon cancer	0.000418	0.00665	CcSEcCtD
Dabigatran etexilate—Gastrooesophageal reflux disease—Capecitabine—colon cancer	0.000415	0.00661	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Capecitabine—colon cancer	0.000415	0.00661	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Capecitabine—colon cancer	0.000412	0.00657	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Irinotecan—colon cancer	0.000407	0.00648	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.000407	0.00648	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—TYMS—colon cancer	0.000402	0.0305	CbGpPWpGaD
Dabigatran etexilate—Cardiac failure—Fluorouracil—colon cancer	0.000399	0.00636	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Capecitabine—colon cancer	0.000397	0.00632	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00039	0.00621	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Fluorouracil—colon cancer	0.00039	0.00621	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Vincristine—colon cancer	0.000376	0.00599	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000366	0.00583	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.000357	0.0271	CbGpPWpGaD
Dabigatran etexilate—Nasopharyngitis—Fluorouracil—colon cancer	0.000348	0.00555	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Capecitabine—colon cancer	0.000343	0.00546	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Irinotecan—colon cancer	0.000342	0.00546	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Capecitabine—colon cancer	0.000339	0.0054	CcSEcCtD
Dabigatran etexilate—Dysphagia—Fluorouracil—colon cancer	0.000337	0.00536	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Fluorouracil—colon cancer	0.000328	0.00522	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Irinotecan—colon cancer	0.000327	0.0052	CcSEcCtD
Dabigatran etexilate—Pneumonia—Vincristine—colon cancer	0.000324	0.00516	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Vincristine—colon cancer	0.000317	0.00505	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Vincristine—colon cancer	0.000316	0.00503	CcSEcCtD
Dabigatran etexilate—Pneumonia—Irinotecan—colon cancer	0.000315	0.00502	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000313	0.00498	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Capecitabine—colon cancer	0.000312	0.00496	CcSEcCtD
Dabigatran etexilate—Bone disorder—Methotrexate—colon cancer	0.000309	0.00492	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Irinotecan—colon cancer	0.000309	0.00492	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Irinotecan—colon cancer	0.000307	0.00489	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Methotrexate—colon cancer	0.000307	0.00489	CcSEcCtD
Dabigatran etexilate—UGT1A9—Irinotecan Pathway—APC—colon cancer	0.000304	0.0231	CbGpPWpGaD
Dabigatran etexilate—ABCB1—embryo—colon cancer	0.000303	0.00387	CbGeAlD
Dabigatran etexilate—Pneumonia—Fluorouracil—colon cancer	0.000302	0.00481	CcSEcCtD
Dabigatran etexilate—Infestation—Fluorouracil—colon cancer	0.0003	0.00478	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Fluorouracil—colon cancer	0.0003	0.00478	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Fluorouracil—colon cancer	0.000296	0.00471	CcSEcCtD
Dabigatran etexilate—Hepatic enzyme increased—Methotrexate—colon cancer	0.000295	0.0047	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Fluorouracil—colon cancer	0.000294	0.00469	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Fluorouracil—colon cancer	0.000292	0.00465	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Vincristine—colon cancer	0.000285	0.00455	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Vincristine—colon cancer	0.000284	0.00452	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Vincristine—colon cancer	0.000283	0.00451	CcSEcCtD
Dabigatran etexilate—Epistaxis—Fluorouracil—colon cancer	0.000283	0.00451	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Irinotecan—colon cancer	0.000283	0.00451	CcSEcCtD
Dabigatran etexilate—Sinusitis—Fluorouracil—colon cancer	0.000282	0.00449	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Irinotecan—colon cancer	0.000281	0.00448	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Capecitabine—colon cancer	0.000279	0.00444	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Irinotecan—colon cancer	0.000277	0.0044	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000272	0.00434	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Capecitabine—colon cancer	0.000272	0.00434	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Capecitabine—colon cancer	0.000272	0.00434	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Fluorouracil—colon cancer	0.000271	0.00431	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Fluorouracil—colon cancer	0.00027	0.00429	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Vincristine—colon cancer	0.000268	0.00427	CcSEcCtD
Dabigatran etexilate—Angiopathy—Vincristine—colon cancer	0.000262	0.00418	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Irinotecan—colon cancer	0.000261	0.00416	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CHST5—colon cancer	0.000261	0.0198	CbGpPWpGaD
Dabigatran etexilate—Mediastinal disorder—Vincristine—colon cancer	0.00026	0.00415	CcSEcCtD
Dabigatran etexilate—Angiopathy—Irinotecan—colon cancer	0.000255	0.00407	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Irinotecan—colon cancer	0.000254	0.00405	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Irinotecan—colon cancer	0.000254	0.00404	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Methotrexate—colon cancer	0.000252	0.00402	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—colon cancer	0.000252	0.0191	CbGpPWpGaD
Dabigatran etexilate—Liver function test abnormal—Capecitabine—colon cancer	0.000251	0.004	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Capecitabine—colon cancer	0.000249	0.00396	CcSEcCtD
Dabigatran etexilate—ABCB1—epithelium—colon cancer	0.000247	0.00315	CbGeAlD
Dabigatran etexilate—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000245	0.00391	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Capecitabine—colon cancer	0.000243	0.00388	CcSEcCtD
Dabigatran etexilate—Back pain—Vincristine—colon cancer	0.000243	0.00388	CcSEcCtD
Dabigatran etexilate—Flatulence—Irinotecan—colon cancer	0.000241	0.00385	CcSEcCtD
Dabigatran etexilate—Gastritis—Capecitabine—colon cancer	0.000241	0.00384	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00024	0.00382	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—TYMS—colon cancer	0.000237	0.018	CbGpPWpGaD
Dabigatran etexilate—Back pain—Irinotecan—colon cancer	0.000237	0.00377	CcSEcCtD
Dabigatran etexilate—Dysphagia—Capecitabine—colon cancer	0.000235	0.00375	CcSEcCtD
Dabigatran etexilate—Influenza—Capecitabine—colon cancer	0.000235	0.00375	CcSEcCtD
Dabigatran etexilate—Anaemia—Vincristine—colon cancer	0.000232	0.0037	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Capecitabine—colon cancer	0.000231	0.00369	CcSEcCtD
Dabigatran etexilate—ABCB1—renal system—colon cancer	0.000229	0.00293	CbGeAlD
Dabigatran etexilate—Angina pectoris—Capecitabine—colon cancer	0.000229	0.00365	CcSEcCtD
Dabigatran etexilate—Anaemia—Irinotecan—colon cancer	0.000226	0.00361	CcSEcCtD
Dabigatran etexilate—Bronchitis—Capecitabine—colon cancer	0.000226	0.0036	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Capecitabine—colon cancer	0.000226	0.00359	CcSEcCtD
Dabigatran etexilate—Syncope—Irinotecan—colon cancer	0.00022	0.0035	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Capecitabine—colon cancer	0.000219	0.00348	CcSEcCtD
Dabigatran etexilate—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000218	0.0165	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Vincristine—colon cancer	0.000217	0.00346	CcSEcCtD
Dabigatran etexilate—Anaemia—Fluorouracil—colon cancer	0.000217	0.00345	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Irinotecan—colon cancer	0.000215	0.00343	CcSEcCtD
Dabigatran etexilate—Cough—Irinotecan—colon cancer	0.000214	0.00341	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CHST5—colon cancer	0.000212	0.0161	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Irinotecan—colon cancer	0.000212	0.00337	CcSEcCtD
Dabigatran etexilate—Pneumonia—Capecitabine—colon cancer	0.000211	0.00336	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Capecitabine—colon cancer	0.00021	0.00334	CcSEcCtD
Dabigatran etexilate—Infestation—Capecitabine—colon cancer	0.00021	0.00334	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Capecitabine—colon cancer	0.000207	0.00329	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Capecitabine—colon cancer	0.000206	0.00328	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Vincristine—colon cancer	0.000205	0.00327	CcSEcCtD
Dabigatran etexilate—Infection—Vincristine—colon cancer	0.000204	0.00325	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Capecitabine—colon cancer	0.000204	0.00325	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Methotrexate—colon cancer	0.000203	0.00323	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Vincristine—colon cancer	0.000201	0.00321	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Vincristine—colon cancer	0.000201	0.0032	CcSEcCtD
Dabigatran etexilate—Haematuria—Capecitabine—colon cancer	0.0002	0.00319	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Irinotecan—colon cancer	0.0002	0.00318	CcSEcCtD
Dabigatran etexilate—Chest pain—Fluorouracil—colon cancer	0.0002	0.00318	CcSEcCtD
Dabigatran etexilate—Infection—Irinotecan—colon cancer	0.000199	0.00316	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Capecitabine—colon cancer	0.000198	0.00316	CcSEcCtD
Dabigatran etexilate—Epistaxis—Capecitabine—colon cancer	0.000198	0.00315	CcSEcCtD
Dabigatran etexilate—Shock—Irinotecan—colon cancer	0.000197	0.00313	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Irinotecan—colon cancer	0.000196	0.00312	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN1A—colon cancer	0.000196	0.0149	CbGpPWpGaD
Dabigatran etexilate—Thrombocytopenia—Irinotecan—colon cancer	0.000196	0.00312	CcSEcCtD
Dabigatran etexilate—Hypotension—Vincristine—colon cancer	0.000192	0.00306	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Fluorouracil—colon cancer	0.000191	0.00305	CcSEcCtD
Dabigatran etexilate—ABCB1—lymphoid tissue—colon cancer	0.00019	0.00243	CbGeAlD
Dabigatran etexilate—Infection—Fluorouracil—colon cancer	0.00019	0.00303	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Capecitabine—colon cancer	0.000189	0.00302	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Capecitabine—colon cancer	0.000188	0.003	CcSEcCtD
Dabigatran etexilate—ABCB1—digestive system—colon cancer	0.000188	0.0024	CbGeAlD
Dabigatran etexilate—Nervous system disorder—Fluorouracil—colon cancer	0.000188	0.00299	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Fluorouracil—colon cancer	0.000187	0.00299	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Methotrexate—colon cancer	0.000187	0.00298	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vincristine—colon cancer	0.000187	0.00298	CcSEcCtD
Dabigatran etexilate—Hypotension—Irinotecan—colon cancer	0.000187	0.00298	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—EP300—colon cancer	0.000186	0.0141	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Capecitabine—colon cancer	0.000186	0.00296	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Capecitabine—colon cancer	0.000186	0.00296	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Capecitabine—colon cancer	0.000185	0.00295	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Capecitabine—colon cancer	0.000185	0.00294	CcSEcCtD
Dabigatran etexilate—Hypotension—Fluorouracil—colon cancer	0.000179	0.00285	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Irinotecan—colon cancer	0.000178	0.00284	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vincristine—colon cancer	0.000177	0.00282	CcSEcCtD
Dabigatran etexilate—Fatigue—Vincristine—colon cancer	0.000177	0.00282	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Irinotecan—colon cancer	0.000176	0.0028	CcSEcCtD
Dabigatran etexilate—Constipation—Vincristine—colon cancer	0.000176	0.0028	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Capecitabine—colon cancer	0.000175	0.00278	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000174	0.00278	CcSEcCtD
Dabigatran etexilate—ABCB1—bone marrow—colon cancer	0.000173	0.00221	CbGeAlD
Dabigatran etexilate—Gastrointestinal disorder—Irinotecan—colon cancer	0.000173	0.00275	CcSEcCtD
Dabigatran etexilate—Fatigue—Irinotecan—colon cancer	0.000172	0.00275	CcSEcCtD
Dabigatran etexilate—Constipation—Irinotecan—colon cancer	0.000171	0.00272	CcSEcCtD
Dabigatran etexilate—Angiopathy—Capecitabine—colon cancer	0.000171	0.00272	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Fluorouracil—colon cancer	0.000171	0.00272	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Capecitabine—colon cancer	0.00017	0.00271	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Capecitabine—colon cancer	0.00017	0.0027	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Fluorouracil—colon cancer	0.000169	0.00268	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—colon cancer	0.000168	0.00267	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Vincristine—colon cancer	0.000168	0.00267	CcSEcCtD
Dabigatran etexilate—ABCB1—vagina—colon cancer	0.000166	0.00212	CbGeAlD
Dabigatran etexilate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000165	0.00263	CcSEcCtD
Dabigatran etexilate—Malnutrition—Capecitabine—colon cancer	0.000164	0.00261	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CA7—colon cancer	0.000164	0.0124	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Irinotecan—colon cancer	0.000163	0.0026	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—colon cancer	0.000163	0.00259	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—MYC—colon cancer	0.000163	0.0123	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Vincristine—colon cancer	0.000162	0.00259	CcSEcCtD
Dabigatran etexilate—Flatulence—Capecitabine—colon cancer	0.000162	0.00257	CcSEcCtD
Dabigatran etexilate—Back pain—Capecitabine—colon cancer	0.000159	0.00253	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Irinotecan—colon cancer	0.000158	0.00252	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—colon cancer	0.000157	0.0025	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—colon cancer	0.000156	0.00249	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—colon cancer	0.000156	0.00249	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000154	0.0117	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Fluorouracil—colon cancer	0.000152	0.00242	CcSEcCtD
Dabigatran etexilate—Anaemia—Capecitabine—colon cancer	0.000152	0.00241	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vincristine—colon cancer	0.000151	0.00241	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—colon cancer	0.000149	0.00237	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—colon cancer	0.000148	0.0113	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—colon cancer	0.000148	0.00235	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—colon cancer	0.000147	0.00235	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Irinotecan—colon cancer	0.000147	0.00235	CcSEcCtD
Dabigatran etexilate—Asthenia—Vincristine—colon cancer	0.000147	0.00235	CcSEcCtD
Dabigatran etexilate—Syncope—Capecitabine—colon cancer	0.000147	0.00234	CcSEcCtD
Dabigatran etexilate—Palpitations—Capecitabine—colon cancer	0.000145	0.00231	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Capecitabine—colon cancer	0.000144	0.0023	CcSEcCtD
Dabigatran etexilate—Asthenia—Irinotecan—colon cancer	0.000143	0.00228	CcSEcCtD
Dabigatran etexilate—Cough—Capecitabine—colon cancer	0.000143	0.00228	CcSEcCtD
Dabigatran etexilate—Hypertension—Capecitabine—colon cancer	0.000142	0.00225	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Fluorouracil—colon cancer	0.000141	0.00225	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—colon cancer	0.000141	0.00224	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vincristine—colon cancer	0.00014	0.00224	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—colon cancer	0.00014	0.00223	CcSEcCtD
Dabigatran etexilate—ABCB1—liver—colon cancer	0.00014	0.00179	CbGeAlD
Dabigatran etexilate—Chest pain—Capecitabine—colon cancer	0.00014	0.00222	CcSEcCtD
Dabigatran etexilate—Arthralgia—Capecitabine—colon cancer	0.00014	0.00222	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000139	0.00221	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—colon cancer	0.000138	0.00221	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—colon cancer	0.000137	0.00219	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Irinotecan—colon cancer	0.000137	0.00218	CcSEcCtD
Dabigatran etexilate—Dizziness—Vincristine—colon cancer	0.000136	0.00216	CcSEcCtD
Dabigatran etexilate—Pruritus—Fluorouracil—colon cancer	0.000135	0.00216	CcSEcCtD
Dabigatran etexilate—Infection—Capecitabine—colon cancer	0.000133	0.00212	CcSEcCtD
Dabigatran etexilate—Dizziness—Irinotecan—colon cancer	0.000132	0.00211	CcSEcCtD
Dabigatran etexilate—Shock—Capecitabine—colon cancer	0.000132	0.0021	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Capecitabine—colon cancer	0.000131	0.00209	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Fluorouracil—colon cancer	0.000131	0.00209	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Capecitabine—colon cancer	0.000131	0.00209	CcSEcCtD
Dabigatran etexilate—Vomiting—Vincristine—colon cancer	0.000131	0.00208	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—colon cancer	0.00013	0.00207	CcSEcCtD
Dabigatran etexilate—Skin disorder—Capecitabine—colon cancer	0.00013	0.00207	CcSEcCtD
Dabigatran etexilate—Rash—Vincristine—colon cancer	0.000129	0.00206	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vincristine—colon cancer	0.000129	0.00206	CcSEcCtD
Dabigatran etexilate—Headache—Vincristine—colon cancer	0.000129	0.00205	CcSEcCtD
Dabigatran etexilate—F2—Thrombin signalling through proteinase activated receptors (PARs)—SRC—colon cancer	0.000127	0.00966	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CCND1—colon cancer	0.000127	0.00965	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Methotrexate—colon cancer	0.000127	0.00203	CcSEcCtD
Dabigatran etexilate—Vomiting—Irinotecan—colon cancer	0.000127	0.00202	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—colon cancer	0.000127	0.00202	CcSEcCtD
Dabigatran etexilate—Dizziness—Fluorouracil—colon cancer	0.000127	0.00202	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—colon cancer	0.000126	0.00201	CcSEcCtD
Dabigatran etexilate—Rash—Irinotecan—colon cancer	0.000126	0.00201	CcSEcCtD
Dabigatran etexilate—Dermatitis—Irinotecan—colon cancer	0.000126	0.00201	CcSEcCtD
Dabigatran etexilate—Headache—Irinotecan—colon cancer	0.000125	0.002	CcSEcCtD
Dabigatran etexilate—Hypotension—Capecitabine—colon cancer	0.000125	0.00199	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—colon cancer	0.000122	0.00194	CcSEcCtD
Dabigatran etexilate—Nausea—Vincristine—colon cancer	0.000122	0.00194	CcSEcCtD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—PIK3CA—colon cancer	0.000122	0.00925	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000122	0.00194	CcSEcCtD
Dabigatran etexilate—Vomiting—Fluorouracil—colon cancer	0.000122	0.00194	CcSEcCtD
Dabigatran etexilate—Rash—Fluorouracil—colon cancer	0.000121	0.00192	CcSEcCtD
Dabigatran etexilate—Dermatitis—Fluorouracil—colon cancer	0.000121	0.00192	CcSEcCtD
Dabigatran etexilate—Headache—Fluorouracil—colon cancer	0.00012	0.00191	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Capecitabine—colon cancer	0.000119	0.0019	CcSEcCtD
Dabigatran etexilate—Nausea—Irinotecan—colon cancer	0.000119	0.00189	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—colon cancer	0.000118	0.00188	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Capecitabine—colon cancer	0.000118	0.00188	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Capecitabine—colon cancer	0.000116	0.00184	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN1A—colon cancer	0.000116	0.00876	CbGpPWpGaD
Dabigatran etexilate—Fatigue—Capecitabine—colon cancer	0.000115	0.00184	CcSEcCtD
Dabigatran etexilate—Constipation—Capecitabine—colon cancer	0.000114	0.00182	CcSEcCtD
Dabigatran etexilate—Nausea—Fluorouracil—colon cancer	0.000114	0.00181	CcSEcCtD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—SRC—colon cancer	0.000113	0.0086	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Methotrexate—colon cancer	0.000113	0.0018	CcSEcCtD
Dabigatran etexilate—F2—Post-translational protein modification—MUC2—colon cancer	0.000111	0.0084	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—EP300—colon cancer	0.00011	0.00834	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Capecitabine—colon cancer	0.000109	0.00174	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—colon cancer	0.000107	0.00137	CbGeAlD
Dabigatran etexilate—Cough—Methotrexate—colon cancer	0.000107	0.0017	CcSEcCtD
Dabigatran etexilate—Urticaria—Capecitabine—colon cancer	0.000106	0.00169	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Capecitabine—colon cancer	0.000106	0.00168	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—colon cancer	0.000104	0.00166	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—colon cancer	0.000104	0.00166	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000103	0.00164	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—colon cancer	0.000102	0.00774	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—colon cancer	9.96e-05	0.00159	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—ODC1—colon cancer	9.93e-05	0.00753	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CHST5—colon cancer	9.93e-05	0.00753	CbGpPWpGaD
Dabigatran etexilate—Infection—Methotrexate—colon cancer	9.9e-05	0.00158	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Capecitabine—colon cancer	9.86e-05	0.00157	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—colon cancer	9.77e-05	0.00156	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—colon cancer	9.75e-05	0.00155	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—colon cancer	9.68e-05	0.00154	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—colon cancer	9.63e-05	0.0073	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Capecitabine—colon cancer	9.6e-05	0.00153	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—colon cancer	9.58e-05	0.00726	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Capecitabine—colon cancer	9.47e-05	0.00151	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB1—colon cancer	9.31e-05	0.00706	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Methotrexate—colon cancer	9.31e-05	0.00148	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Capecitabine—colon cancer	9.16e-05	0.00146	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—colon cancer	9.08e-05	0.00145	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	8.98e-05	0.00681	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Methotrexate—colon cancer	8.88e-05	0.00141	CcSEcCtD
Dabigatran etexilate—Dizziness—Capecitabine—colon cancer	8.85e-05	0.00141	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—colon cancer	8.77e-05	0.0014	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—colon cancer	8.6e-05	0.00137	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—colon cancer	8.59e-05	0.00137	CcSEcCtD
Dabigatran etexilate—Vomiting—Capecitabine—colon cancer	8.51e-05	0.00136	CcSEcCtD
Dabigatran etexilate—Rash—Capecitabine—colon cancer	8.44e-05	0.00134	CcSEcCtD
Dabigatran etexilate—Dermatitis—Capecitabine—colon cancer	8.43e-05	0.00134	CcSEcCtD
Dabigatran etexilate—Headache—Capecitabine—colon cancer	8.38e-05	0.00134	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—colon cancer	8.15e-05	0.0013	CcSEcCtD
Dabigatran etexilate—Nausea—Capecitabine—colon cancer	7.95e-05	0.00127	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—colon cancer	7.91e-05	0.00126	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—colon cancer	7.87e-05	0.00125	CcSEcCtD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—PIK3CA—colon cancer	7.65e-05	0.0058	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA7—colon cancer	7.46e-05	0.00566	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	7.42e-05	0.00563	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Methotrexate—colon cancer	7.34e-05	0.00117	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	7.22e-05	0.00547	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methotrexate—colon cancer	7.15e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—colon cancer	7.05e-05	0.00112	CcSEcCtD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—AKT1—colon cancer	7.04e-05	0.00534	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—colon cancer	7.01e-05	0.00532	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Methotrexate—colon cancer	6.82e-05	0.00109	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—colon cancer	6.78e-05	0.00514	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	6.68e-05	0.00507	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	6.63e-05	0.00503	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FGFR3—colon cancer	6.6e-05	0.005	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Methotrexate—colon cancer	6.59e-05	0.00105	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	6.45e-05	0.00489	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Methotrexate—colon cancer	6.33e-05	0.00101	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	6.33e-05	0.0048	CbGpPWpGaD
Dabigatran etexilate—Rash—Methotrexate—colon cancer	6.28e-05	0.001	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—colon cancer	6.27e-05	0.000999	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—colon cancer	6.24e-05	0.000994	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CDX2—colon cancer	6.18e-05	0.00469	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	6.13e-05	0.00465	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA7—colon cancer	6.06e-05	0.0046	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—APC—colon cancer	6.06e-05	0.00459	CbGpPWpGaD
Dabigatran etexilate—Nausea—Methotrexate—colon cancer	5.92e-05	0.000942	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—BRAF—colon cancer	5.69e-05	0.00432	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—PPARG—colon cancer	5.65e-05	0.00428	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—colon cancer	5.54e-05	0.0042	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	5.53e-05	0.00419	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB1—colon cancer	5.49e-05	0.00416	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MUC2—colon cancer	5.26e-05	0.00399	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—colon cancer	5.25e-05	0.00398	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—SRC—colon cancer	5.16e-05	0.00391	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—colon cancer	4.96e-05	0.00376	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	4.56e-05	0.00346	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CHST5—colon cancer	4.52e-05	0.00343	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ODC1—colon cancer	4.52e-05	0.00343	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DLC1—colon cancer	4.31e-05	0.00327	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—colon cancer	4.27e-05	0.00324	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LGR5—colon cancer	4.05e-05	0.00307	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PIK3CA—colon cancer	3.92e-05	0.00298	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	3.84e-05	0.00291	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	3.81e-05	0.00289	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—colon cancer	3.7e-05	0.0028	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ODC1—colon cancer	3.67e-05	0.00279	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CHST5—colon cancer	3.67e-05	0.00279	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—colon cancer	3.63e-05	0.00275	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	3.62e-05	0.00274	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—colon cancer	3.58e-05	0.00271	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—colon cancer	3.26e-05	0.00247	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—colon cancer	3.15e-05	0.00239	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—colon cancer	3.08e-05	0.00234	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	3.07e-05	0.00233	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AXIN2—colon cancer	2.91e-05	0.00221	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—colon cancer	2.83e-05	0.00215	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	2.82e-05	0.00214	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA7—colon cancer	2.78e-05	0.00211	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SRC—colon cancer	2.71e-05	0.00206	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—colon cancer	2.67e-05	0.00202	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—colon cancer	2.64e-05	0.002	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ABCB1—colon cancer	2.62e-05	0.00199	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TYMS—colon cancer	2.58e-05	0.00195	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—colon cancer	2.56e-05	0.00194	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	2.55e-05	0.00193	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	2.49e-05	0.00189	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—colon cancer	2.47e-05	0.00187	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—colon cancer	2.43e-05	0.00184	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—colon cancer	2.43e-05	0.00184	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	2.42e-05	0.00183	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—colon cancer	2.36e-05	0.00179	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	2.35e-05	0.00178	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	2.3e-05	0.00174	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	2.27e-05	0.00172	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	2.11e-05	0.0016	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—colon cancer	2.09e-05	0.00159	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	2.06e-05	0.00157	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	1.95e-05	0.00148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—colon cancer	1.92e-05	0.00146	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—colon cancer	1.83e-05	0.00138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	1.73e-05	0.00131	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.69e-05	0.00128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ODC1—colon cancer	1.69e-05	0.00128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CHST5—colon cancer	1.69e-05	0.00128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	1.54e-05	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.52e-05	0.00115	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—colon cancer	1.44e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—colon cancer	1.44e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SRC—colon cancer	1.4e-05	0.00106	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—colon cancer	1.36e-05	0.00103	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—colon cancer	1.35e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	1.31e-05	0.000994	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—colon cancer	1.25e-05	0.000948	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—colon cancer	1.22e-05	0.000923	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.22e-05	0.000923	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—colon cancer	1.19e-05	0.000906	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—colon cancer	1.19e-05	0.000906	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.19e-05	0.000905	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.18e-05	0.000898	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—colon cancer	1.17e-05	0.00089	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.17e-05	0.00089	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—colon cancer	1.16e-05	0.000878	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.15e-05	0.000869	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.09e-05	0.000827	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—colon cancer	1.06e-05	0.000807	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.06e-05	0.000804	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.03e-05	0.000783	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—colon cancer	1.03e-05	0.000781	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.92e-06	0.000753	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—colon cancer	9.84e-06	0.000747	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—colon cancer	9.71e-06	0.000736	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—colon cancer	9.54e-06	0.000723	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	9.5e-06	0.000721	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	9.48e-06	0.000719	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	9.29e-06	0.000705	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—colon cancer	8.83e-06	0.00067	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	8.78e-06	0.000666	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—colon cancer	8.69e-06	0.000659	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR3—colon cancer	8.41e-06	0.000638	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—colon cancer	8.31e-06	0.00063	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	8.06e-06	0.000612	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	7.8e-06	0.000592	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—colon cancer	7.72e-06	0.000586	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—colon cancer	7.72e-06	0.000586	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.34e-06	0.000557	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—colon cancer	7.26e-06	0.000551	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—colon cancer	7.22e-06	0.000547	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—colon cancer	7.04e-06	0.000534	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—colon cancer	6.75e-06	0.000512	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—colon cancer	6.72e-06	0.00051	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—colon cancer	6.65e-06	0.000504	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	6.59e-06	0.0005	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—colon cancer	6.54e-06	0.000496	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—colon cancer	6.11e-06	0.000463	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—colon cancer	5.65e-06	0.000428	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—colon cancer	5.49e-06	0.000417	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—colon cancer	5.44e-06	0.000413	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—colon cancer	5.44e-06	0.000412	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—colon cancer	5.31e-06	0.000403	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—colon cancer	5.3e-06	0.000402	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—colon cancer	5.25e-06	0.000398	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—colon cancer	5.12e-06	0.000389	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—colon cancer	4.99e-06	0.000378	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—colon cancer	4.88e-06	0.00037	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—colon cancer	4.74e-06	0.00036	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—colon cancer	4.62e-06	0.00035	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—colon cancer	4.56e-06	0.000346	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—colon cancer	4.42e-06	0.000335	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—colon cancer	4.37e-06	0.000332	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—colon cancer	4.25e-06	0.000322	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—colon cancer	4.24e-06	0.000321	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—colon cancer	4.16e-06	0.000315	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—colon cancer	4.02e-06	0.000305	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—colon cancer	3.93e-06	0.000298	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—colon cancer	3.61e-06	0.000274	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—colon cancer	3.49e-06	0.000265	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—colon cancer	3.34e-06	0.000253	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—colon cancer	3.29e-06	0.000249	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—colon cancer	3.27e-06	0.000248	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—colon cancer	3.1e-06	0.000235	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—colon cancer	2.95e-06	0.000223	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—colon cancer	2.67e-06	0.000203	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—colon cancer	2.44e-06	0.000185	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—colon cancer	2.03e-06	0.000154	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—colon cancer	1.5e-06	0.000114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—colon cancer	1.23e-06	9.29e-05	CbGpPWpGaD
